SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Transkaryotic Therapies (TKTX) -- Ignore unavailable to you. Want to Upgrade?

To: paradigm7241 who wrote (2)4/21/2000 10:20:00 AM
From: scaram(o)uche  Respond to of 12
 
Paradigm:

Your view is shared among most of those who (1) know the sector, and (2) I come in contact with. It's largely unchanged now (the "lean") for a couple of years.

Will NESP make the point largely moot?

There was already an existent TKTX thread. Nice to try to keep the place as tidy as possible.

Rick



To: paradigm7241 who wrote (2)4/21/2000 1:17:00 PM
From: david james  Respond to of 12
 
I believe that Amgen's method is substantially quite different from that of TKTX and therefore should not be covered in the Amgen patent. However, the real question is whether Amgen can keep up the legal proceedings for several years and effectively block TKTXs product from getting to market. In three years or so, I believe Amgen's patent runs out anyway. So the question to me is how long Amgen can stall.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News